The Indian local therapeutics market comprising of all biologics and vaccines for March 2012 has been estimated to be worth $700 million, while the statins market stood at $125 million, according to IMS Health. In the therapeutic space in India, insulin is leading the table with $250 million followed by heparins with $70 million, gonadotrophins at $50 million, and hepatitis-B vaccine and combination vaccines at $200 million.

The Genetic Engineering Approval Committee (GEAC) has given approval to 20 recombinant therapeutics products as of March 2012, for marketing in India. Since 2005, the Review Committee on Genetic Manipulation (RCGM) from GEAC has recommended 91 clinical trials to be conducted in India related to recombinant pharmaceutical and therapeutic products with the permission of Drug Controller General of India.

There are about 100 core biopharmaceutical companies that are into research and development, manufacturing, and marketing of biologics in India. The rest of the companies, both local and multinationals are into only trading activities.

While there were 14 therapeutic drugs with 50 brands in 2005, India now has 250 brands in 20 therapeutic products. There are 10 companies offering about 40 brands of insulin range of products. The other leading therapeutic products that have a good number of brands include Erythropoietin with 55 brands; Human Chorionic Gonadotropin with 48 brands; Streptokinase with 33 brands; while Interferon and Heparins have 10 brands each.

There over 400 brands available in India for seven different statins. There is a lot of competition in the Atorvastatin space as there are close to 300 brands available in the market. There are about 25-60 brands for Simvastatin, Rosuvastatin and Lovastatin. On the contrary Fluvastatin, Pravastatin and Pitavastatin have no competition in the market as these products have just three brands in the market.